Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 1997

View Archived Issues

DuPont Merck receives FDA approval for nuclear imaging breast cancer test

Positive efficacy profile reported for Zonagen's Vasomax

Preliminary results from phase I trial of Nortran's RSD-921 reported

Meridian receives approval to market its E. coli detection kit in Japan

Monarch acquires ocular therapy from Glaxo Wellcome

Biomira notified of patent allowance for Theratope

Eisai develops agents for brain cancer

Inhibitors of IL-1beta/IL-6 production from Taisho

Daiichi reports compounds for RA, allergy and transplant rejection

Antiemetics described by Dainippon

Yamanouchi discloses Na+/H+ exchange inhibitors

New agents for atherosclerosis from Bayer

Antifibrotic agents claimed by Hoechst

Hoechst discloses agents for immune/autoimmune and other disorders

Anxiolytic/nootropic agents from Asahi

Therapeutic strategies for treating disorders of gastric emptying reported at DDW

New antidiarrheal agent reported at DDW

French scientists study role of tachykinins in colitis

MF-59 adjuvant enhances immunogenicity of HBV vaccine

New developments in chemotherapy reported at DDW

Oxis International moves IBD therapy to phase II

New medicines under development for IBD reported at DDW

Carvedilol approved by FDA for CHF

Gilead's oral influenza drug enters phase II

New immunomodulator from Orion with potential in IBD

Janssen characterizes new enterokinetic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.